Salarius Pharmaceuticals Statistics
Total Valuation
SLRX has a market cap or net worth of $2.45 million. The enterprise value is -$866,088.
| Market Cap | 2.45M |
| Enterprise Value | -866,088 |
Important Dates
The next estimated earnings date is Monday, November 11, 2024, after market close.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SLRX has 1.44 million shares outstanding. The number of shares has increased by 69.10% in one year.
| Shares Outstanding | 1.44M |
| Shares Change (YoY) | +69.10% |
| Shares Change (QoQ) | +14.51% |
| Owned by Insiders (%) | 2.52% |
| Owned by Institutions (%) | 2.15% |
| Float | 1.40M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.98
| Current Ratio | 2.98 |
| Quick Ratio | 2.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -119.83% and return on invested capital (ROIC) is -78.11%.
| Return on Equity (ROE) | -119.83% |
| Return on Assets (ROA) | -53.99% |
| Return on Capital (ROIC) | -78.11% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.23M |
| Employee Count | 2 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.09% in the last 52 weeks. The beta is 0.96, so SLRX's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -73.09% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 3.19 |
| Relative Strength Index (RSI) | 51.44 |
| Average Volume (20 Days) | 937,170 |
Short Selling Information
The latest short interest is 1,528, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 1,528 |
| Short Previous Month | 15,020 |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.11% |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6.74M |
| Pretax Income | -6.46M |
| Net Income | -6.46M |
| EBITDA | -6.73M |
| EBIT | -6.74M |
| Earnings Per Share (EPS) | -$12.42 |
Balance Sheet
| Cash & Cash Equivalents | 3.27M |
| Total Debt | n/a |
| Net Cash | 3.27M |
| Net Cash Per Share | $2.27 |
| Equity (Book Value) | 2.38M |
| Book Value Per Share | 3.70 |
| Working Capital | 2.34M |
Cash Flow
| Operating Cash Flow | -7.69M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.69M |
| FCF Per Share | -$5.33 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -69.10% |
| Shareholder Yield | -69.10% |
| Earnings Yield | -268.59% |
| FCF Yield | -319.37% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 17, 2024. It was a reverse split with a ratio of 0.125:1.
| Last Split Date | Jun 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.125:1 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |